Table 3.
Difference-in-differences estimates (in percentage points) for change in percentage of participants using healthcare service after the week of a positive polymerase chain reaction test result for SARS-CoV-2, with participants who tested negative as comparison group
| Age group and weeks after test result | Primary care | Specialist care | |||
|---|---|---|---|---|---|
| Percentage points difference in weekly rate of use: β* (95% CI) | % relative difference* (95% CI) | Percentage points difference in weekly rate of use: β* (95% CI) | % relative difference* (95% CI) | ||
| 1-5 years | |||||
| 1-4 | 11.35 (10.33 to 12.37) | 339 (308 to 369) | 0.12 (−0.24 to 0.49) | 4 (−7 to 15) | |
| 5-8 | 0.74 (0.15 to 1.33) | 22 (4 to 40) | 0.08 (−0.35 to 0.52) | 3 (−10 to 15) | |
| 9-12 | 0.88 (0.23 to 1.53) | 26 (7 to 46) | 0.08 (−0.36 to 0.51) | 2 (−11 to 15) | |
| 13-24† | 0.42 (−0.02 to 0.86) | 13 (−0 to 26) | 0.11 (−0.45 to 0.24) | −3 (−14 to 7) | |
| 6-15 years | |||||
| 1-4 | 11.42 (10.92 to 11.92) | 471 (450 to 491) | 0.18 (−0.03 to 0.38) | 7 (−1 to 16) | |
| 5-8 | 0.34 (0.04 to 0.64) | 14 (2 to 26) | 0.07 (−0.16 to 0.30) | 3 (−6 to 13) | |
| 9-12 | 0.37 (0.07 to 0.67) | 15 (3 to 28) | −0.12 (−0.36 to 0.12) | −5 (−15 to 5) | |
| 13-24† | 0.01 (−0.20 to 0.22) | 0 (−8 to 9) | −0.40 (−0.62 to −0.17) | −16 (−25 to 5) | |
| 16-19 years | |||||
| 1-4 | 12.57 (11.91 to 13.23) | 401 (380 to 422) | 0.17 (−0.09 to 0.43) | 6 (−3 to 14) | |
| 5-8 | 0.34 (−0.06 to 0.75) | 11 (−2 to 24) | −0.19 (−0.46 to 0.09) | −6 (−15 to 3) | |
| 9-12 | 0.20 (−0.21 to 0.60) | 6 (−7 to 19) | −0.41 (−0.71 to −0.10) | −13 (−23 to −3) | |
| 13-24† | −0.32 (−0.60 to −0.04) | −10 (−19 to −1) | −0.46 (−0.77 to −0.15) | −15 (−25 to −5) | |
All models included categorical variables for healthcare use in weeks 13-24 before test week, test week, age, sex, calendar month, country of birth, and comorbidities.
*
Adjusted for confounders. Compared with rate of use during 1-12 weeks before the test for participants who tested negative.
†
Includes observations for weeks 25-36 for some participants.